Rodriguez-Iturbe Bernardo, Pons Hector, Johnson Richard J
Renal Service, Hospital Universitario, Universidad del Zulia, and Instituto Venezolano de Investigaciones Científicas (IVIC)-Zulia, Maracaibo, Venezuela; and Division of Renal Diseases and Hypertension, University of Colorado, Anschutz Campus, Aurora, Colorado.
Physiol Rev. 2017 Jul 1;97(3):1127-1164. doi: 10.1152/physrev.00031.2016.
High blood pressure is present in more than one billion adults worldwide and is the most important modifiable risk factor of death resulting from cardiovascular disease. While many factors contribute to the pathogenesis of hypertension, a role of the immune system has been firmly established by a large number of investigations from many laboratories around the world. Immunosuppressive drugs and inhibition of individual cytokines prevent or ameliorate experimental hypertension, and studies in genetically-modified mouse strains have demonstrated that lymphocytes are necessary participants in the development of hypertension and in hypertensive organ injury. Furthermore, immune reactivity may be the driving force of hypertension in autoimmune diseases. Infiltration of immune cells, oxidative stress, and stimulation of the intrarenal angiotensin system are induced by activation of the innate and adaptive immunity. High blood pressure results from the combined effects of inflammation-induced impairment in the pressure natriuresis relationship, dysfunctional vascular relaxation, and overactivity of the sympathetic nervous system. Imbalances between proinflammatory effector responses and anti-inflammatory responses of regulatory T cells to a large extent determine the severity of inflammation. Experimental and human studies have uncovered autoantigens (isoketal-modified proteins and heat shock protein 70) of potential clinical relevance. Further investigations on the immune reactivity in hypertension may result in the identification of new strategies for the treatment of the disease.
全球超过10亿成年人患有高血压,高血压是心血管疾病导致死亡的最重要的可改变风险因素。虽然许多因素促成了高血压的发病机制,但世界各地许多实验室的大量研究已确凿证实免疫系统在其中发挥作用。免疫抑制药物和对单个细胞因子的抑制可预防或改善实验性高血压,对基因改造小鼠品系的研究表明,淋巴细胞是高血压发展及高血压性器官损伤的必要参与者。此外,免疫反应性可能是自身免疫性疾病中高血压的驱动因素。先天性和适应性免疫的激活会诱导免疫细胞浸润、氧化应激以及肾内血管紧张素系统的刺激。高血压是炎症引起的压力-利钠关系受损、血管舒张功能障碍和交感神经系统过度活跃共同作用的结果。促炎效应反应与调节性T细胞的抗炎反应之间的失衡在很大程度上决定了炎症的严重程度。实验研究和人体研究已发现具有潜在临床相关性的自身抗原(异前列腺素修饰蛋白和热休克蛋白70)。对高血压免疫反应性的进一步研究可能会带来该疾病治疗新策略的发现。